Biomarkers for assessment of the polychemotherapy results in patients with adrenocortical cancer based on gas chromatography-mass spectrometry studies of urine steroid profiles
Authors:
- Ludmila I. VelikanovaLVLudmila I. Velikanova
- Natalia V. VorokhobinaNVNatalia V. Vorokhobina
- Valentina V. KaluginaVKValentina V. Kalugina
- Zulfiya R. ShafigullinaZSZulfiya R. Shafigullina
- Ekaterina V. MalevanayaEMEkaterina V. Malevanaya
- Elena G. StrelnikovaESElena G. Strelnikova
- Vahan Y. BokhyanVBVahan Y. Bokhyan
Open Access
- 22 April 2024
- journal article
- research article
- Published by Moscow Regional Research and Clinical Institute (MONIKI) in Almanac of Clinical Medicine
- Vol. 52 (1) , 17-24
Abstract
Background: The effectiveness of polychemotherapy (PCT) for adrenocortical cancer (ACC) is assessed by imaging tests with the RECIST 1.1 criteria. However, the presence of subclinical tumor foci does not allow for an objective measurement of the true tumor burden. As shown previously, postoperative assessment of the steroid metabolome by gas chromatography-mass spectrometry (GCMS) in ACC patients makes it possible to identify early signs of adrenal steroidogenesis abnormalities and of the recurrence of adrenocortical carcinoma. Aim: To identify biomarkers of response to PCT by GCMS study of the urine steroid profile in ACC patients after surgical resection of the tumor. Materials and methods: Urine steroid profiles were studied by GCMS (Shimadzu GCMS-TQ8050 gas chromatography-mass spectrometer) in 30 ACC patients (stages II, III and IV) after surgery and first line (combination of etoposide, doxorubicin and cisplatin with daily mitotane) and second line (gemcitabine combined with capecitabine and mitotane) PCT. The control group included 25 patients with hormonally inactive adenomas. Results: The response to PCT according to RECIST 1.1 criteria was obtained in 23 patients (Group 1, responders) and in 7 patients ACC progressed under PCT (Group 2, non-responders). In the responders, the urinary excretion of etiocholanolone, pregnanediol and pregnanetriol was lower than in the control group. The non-responders had higher urinary excretion of androgens, progestogens and tetrahydro-11-deoxycortisol (THS), compared to the responders and the control group. The patients with ACC progression under PCT had an increase in 3β,16,20-pregnenetriol (3β,16,20-dP3) levels and a decrease of the 3α,16,20-dP3/3β,16,20-dP3 ratio, compared to those in the PCT responders. The threshold values for urinary excretion of dehydroepiandrosterone (DHEA, ≤ 469 mcg/24h; AUC = 1.0), THS (≤ 223 mcg/24h; AUC = 1.0), and 3β,16,20-dP3 (≤ 130 mcg/24h; AUC = 0.986), as well as the 3α,16,20-dP3/3β,16,20-dP3 ratio (≥ 2.13; AUC = 1.0) had 100% sensitivity and specificity for the assessment of the PCT effectiveness. Conclusion: Different urine steroid profiles were obtained by GCMS in the ACC patients after PCT with and without treatment response. The 100% sensitivity and specificity of the threshold values for urinary excretion of DHEA, THS, 3β,16,20-dP3 and the 3α,16,20-dP3/3β,16,20-dP3 ratio for the assessment of PCT results indicate the potential to use these parameters as biomarkers of response or progression of the disease in the monitoring of PCT effects in ACC patients.Keywords
This publication has 21 references indexed in Scilit:
- Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2020
- Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 2019
- European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal TumorsEuropean Journal of Endocrinology, 2018
- ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomasEuropean Journal of Endocrinology, 2018
- Generation of urinary steroid profiles in patients with adrenal incidentaloma using gas chromatography–mass spectrometryJournal of Analytical Chemistry, 2016
- Different Types of Urinary Steroid Profiling Obtained by High-Performance Liquid Chromatography and Gas Chromatography-Mass Spectrometry in Patients with Adrenocortical CarcinomaDiscover Oncology, 2016
- Observer variability in RECIST-based tumour burden measurements: a meta-analysisEuropean Journal of Cancer, 2016
- Combination Chemotherapy in Advanced Adrenocortical CarcinomaNew England Journal of Medicine, 2012
- Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal TumorsThe Journal of Clinical Endocrinology & Metabolism, 2011
- Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinomaCancer, 2009